Shares of Pharming Group (NASDAQ:PHAR - Get Free Report) gapped up prior to trading on Thursday . The stock had previously closed at $9.38, but opened at $9.67. Pharming Group shares last traded at $9.67, with a volume of 513 shares.
Analysts Set New Price Targets
A number of research analysts have recently weighed in on PHAR shares. Jefferies Financial Group started coverage on Pharming Group in a research report on Monday, December 9th. They set a "buy" rating and a $14.00 price objective for the company. HC Wainwright restated a "buy" rating and set a $37.00 price target on shares of Pharming Group in a report on Tuesday, December 17th. Finally, Oppenheimer decreased their price objective on Pharming Group from $31.00 to $30.00 and set an "outperform" rating on the stock in a report on Monday, October 28th.
Read Our Latest Stock Analysis on PHAR
Pharming Group Price Performance
The stock has a market capitalization of $678.98 million, a PE ratio of -38.50 and a beta of -0.08. The company has a current ratio of 3.53, a quick ratio of 2.76 and a debt-to-equity ratio of 0.41. The firm's 50-day moving average price is $8.82 and its 200-day moving average price is $8.37.
Hedge Funds Weigh In On Pharming Group
A hedge fund recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its position in shares of Pharming Group (NASDAQ:PHAR - Free Report) by 75.4% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 41,110 shares of the company's stock after buying an additional 17,675 shares during the quarter. Silverberg Bernstein Capital Management LLC owned 0.06% of Pharming Group worth $339,000 as of its most recent filing with the Securities & Exchange Commission. 0.03% of the stock is currently owned by institutional investors and hedge funds.
Pharming Group Company Profile
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
See Also
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
